novel Treatment Shows Promise for Gastroesophageal Reflux disease and NSAID-Induced Ulcers

At the Digestive Disease Week (DDW) 2025 conference in San Diego, Daewoong Pharmaceuticals unveiled compelling clinical research data concerning their PE-CAB-based treatment for gastrointestinal ailments.The presentation, which took place between March 3rd and 6th, highlighted the drug’s efficacy in treating gastroesophageal reflux disease (GERD) in Indian patients and preventing ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs).

Superior Efficacy in Treating Gastroesophageal Reflux Disease

the Phase III clinical trial results for native GERD patients demonstrated that Daewoong’s Pec Succulu achieved a superior healing rate compared to esomeprazole, a proton pump inhibitor (PPI). The eight-week treatment period showed meaningful advancement in key symptoms such as chest burning and regurgitation. Furthermore, the Clinical Global Impression of Improvement (CGI-I) scores revealed that 96.2% of patients in the treatment group experienced symptom improvement, compared to 87.8% in the control group.

The P-CAB formulation, which can be an alternative to the PPI formulation, showed a consistent symptom of the day and night due to the continuous suppression of gastric acid secretion. It is characteristic that it solved the problem of night symptoms due to half -life.

Dr. Pravin, India

Dr. Pravin from India, who presented the findings at the conference, emphasized the drug’s ability to provide consistent symptom control throughout the day and night due to its sustained gastric acid suppression.This addresses a common issue with traditional PPIs, which frequently enough fail to adequately control nighttime symptoms.Daewoong Pharmaceuticals launched Pec Succulu in India last month, capitalizing on these promising clinical outcomes.

protecting Against NSAID-Induced Ulcers: A Comparative Study

In a separate clinical trial, Daewoong Pharmaceuticals evaluated the effectiveness of Pec Succulu in preventing peptic ulcers in patients taking NSAIDs. The study compared Pec Succulu to lansoprazole, another PPI commonly used for ulcer prevention. The results indicated that Pec Succulu demonstrated a lower incidence of peptic ulcers compared to lansoprazole. Specifically, at the 24-week mark, the ulcer incidence was 1.16% (2/172) in the Pec Succulu group, compared to 2.76% (5/181) in the lansoprazole group.

it will be a more effective and safer peptic ulcer prevention option for patients with musculoskeletal diseases that have to take long -term anti -inflammatory drugs.

Lee Chang -geun, Professor of Internal Medicine, Seoul Asan Hospital

Professor Lee Chang-geun of seoul Asan Hospital, a participant in the clinical trial, highlighted the potential of Pec Succulu as a safer and more effective option for patients with musculoskeletal conditions who require long-term NSAID use. NSAIDs, while effective for pain relief, are known to increase the risk of peptic ulcers, affecting millions globally.A recent study published in the American Journal of Gastroenterology estimates that up to 20% of chronic NSAID users develop ulcers.

Future Implications and Market Positioning

Lee Ji-sun, head of the clinical progress centre at Daewoong Pharmaceutical, expressed optimism about the drug’s future, stating that the published clinical results from both domestic and international trials at DDW 2025 underscore the potential for expanding the indications of Pec Succulu and solidifying its position as a next-generation treatment for gastrointestinal diseases.The global market for GERD and peptic ulcer treatments is substantial,with projections estimating it to reach over $10 billion by 2027.